Novartis AG (NVS)
132.43
-1.29
(-0.96%)
USD |
NYSE |
Dec 04, 16:00
132.42
-0.01
(-0.01%)
Pre-Market: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 254.11B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 34.82% |
| Valuation | |
| PE Ratio | 18.06 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.793 |
| Price to Book Value | 5.732 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 3.994 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.7224 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 20.42% |
Profile
| Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland. |
| URL | http://www.novartis.com |
| Investor Relations URL | https://www.novartis.com/investors |
| HQ State/Province | Basel-Stadt (Basle Town) |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Feb. 04, 2026 |
| Last Earnings Release | Oct. 28, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 12, 2025 |
Ratings
Profile
| Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland. |
| URL | http://www.novartis.com |
| Investor Relations URL | https://www.novartis.com/investors |
| HQ State/Province | Basel-Stadt (Basle Town) |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Feb. 04, 2026 |
| Last Earnings Release | Oct. 28, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Mar. 12, 2025 |